Clinical correlates of left ventricular hypertrophy in black patients with arterial hypertension

Cardiovascular Journal of South Africa

Volumn 17, Issue 1, 2006, Pages 7-11

  Lepira, F B ^a   Kayembe, P K ^a   M'Buyamba Kabangu, J R ^b   Nseka, M N ^a  

^a University of Kinshasa Hospital   (Congo)

^b UNIVERSITY OF KINSHASA   (Congo)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; GLUCOSE BLOOD LEVEL; HEART INJURY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LIPID ANALYSIS; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PULSE PRESSURE; UNIVARIATE ANALYSIS;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CASE-CONTROL STUDIES; DEMOCRATIC REPUBLIC OF THE CONGO; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LIPIDS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK FACTORS;

EID: 33646270609     PISSN: 10159657     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Sechi AL, Kronenberg F, De Carli S, Falleti E, Zingero L, Catena C, et al. Association of serum lipoprotein (a) levels and apolipoprotein (a) size polymorphism with target organ damage in arterial hypertension. J Am Med Assoc 1997; 277: 1689-1695.
2. Mensah A, Croft JB, Giles WB. The heart, kidney and brain as target organs in hypertension. Cardiol Clin 2002; 20(2): 225-247.
3. Mensah GA, Barkey NL, Cooper RS. Spectrum of target organ damage in Africa: areview of published studies. J Hum Hypertens 1994; 8(11): 799-808.
4. Sander SE, Giles TD. Hypertension and lipids: lipid risk factors in the hypertension syndrome. Curr Hypertens Rep 2002; 4(6): 458-463.
5. Alexander RW. Hypertension and the pathogenesis of atherosclerosis: Oxidative stress and the mediation of arterial inflammatory response: A perspective. Hypertension 1995; 25: 155-161.
6. Borghi C. Interactions between hypercholesterolemia and hypertension: implications for therapy. Curr Opin Nephrol Hypertens 2002; 11(5): 484-496.
7. Chobanian AV, Alexander RW. Exacerbation of atherosclerosis by hypertension: potential mechanisms and clinical implications. Arch Intern Med 1996; 156: 1952-1956.
8. Manninen V, Tenkanen L, Kaskinen P, Kattunen JK, Mänttäri M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on Coronary Heart Disease risk in the Helsinki Heart Study: implications for treatment. Circulation 19992; 85: 37-45.
9. Fruckart JC, Duriez P. HDL and triglycerides as therapeutic targets. Curr Opin Lipidol 2002; 13(6): 605-616.
10. Guidelines Subcommittee World Health Organization/International Society of Hypertension. Hypertension Guidelines for the management of hypertension. J Hypertens 1999; 17: 151-183.
11. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JNC 7. J Am Med Assoc 2003; 289: 2560-2572.
12. M'Buyamba-Kabangu JR Correlates of blood pressure in rural and urban Zaire. J Hypertens 1987; 5: 371-375.
13. Tambwe M, Mbala-Mukendi M, Dikassa LN, M'Buyamba-Kabangu JR. Morbidity and mortality in hospitalized Zarean adults. South Afr J Med 1995; 85: 74.
14. Mbaraga N, Longo-Mbensa B, Tshiani K. Arterial hypertension at the Teaching Hospital of Kinshasa. Trop Cardiol 1989; 85-89.
15. M'Buyamba-Kabangu JR, Lepira FB, Fagard R, Lijnen P, Ditu M, Tshiani K. Relative potency of a beta blocking and a caldium entry blocking agent as antihypertensive drugs in black patients. Eur J Clin Pharmacol 1986; 29: 523-527.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of LDL-cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-508.
17. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
18. Schaeffner ES, Kurth T, Curham GC, Glynn RJ, Rexrode KM, Baignet C, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14: 2084-2091.
19. Fogari R, Zoppi A, Marasi G, Vanasia A, Villa G. Association between plasma fibrinogen levels and cardiovascular risk factors in hypertensive men. J Cardiovasc Risk 1994; 1: 341-345.
20. De Kreutzenberg SV, Avogaro A, Tiengo A, Del Prato S. Left ventricular mass in type 2 diabetes mellitus. A study employing a simple ECG index: the Cornell voltage index. J Endocrinol Invest 2000; 23(3): 139-144.
21. El-Gharbawy AH, Kotchen JM, Grim CE, Kaldunski M, Hoffmann RG, Pausova Z, et al. Predictors of target organ damage in hypertensive blacks and whites. Hypertension 2001; 38(4): 761-766.
22. Hussein AA, El Zubier AG, Ahmed GE. Target organ involvement in hypertensive patients in Eastern Sudan. J Hum Hypertens 1999; 13(1): 9-12.
23. Ajayi OO, Akinwusi PO. Spectrum of hypertensive heart disease in Nigerians: cross sectional study of echocardiographic indices and their correlation with treadmill exercise capacity. J Hypertens 1993; 11(1): 99-102.
24. Smith SM, Mensah GA. Population aging and implications for epidemic cardiovascular disease in Sub-Saharan Africa. Ethn Dis 2003; 13(2 Suppl 2): S77-80.
25. Tuomilehto J. Impact of age on cardiovascular risk: implications for cardiovascular disease management. Atheroscler Suppl 2004; 5(2): 9-17.
26. Kenchaiah S, Pfeffer MA. Cardiac remodelling in systemic hypertension. Med Clin North Am 2004; 88(1): 115-130.
27. Simon G. Pathogenesis of structural vascular changes in hypertensives. J Hypertens 2004; 22(1): 3-10.
28. Benetos A, Waeber B, Izzo J, Mitchell G, Resnick L, Asmar R, Safar M. Influence of age, risk factors and cardiovascular and renal disease on arterial stiffness: clinical implications. Am J Hypertens 2002; 15(12): 1101-1108.
29. Viazzi F, Leoncini G, Parodi D, Ravera M, Ratto E, Vettoretti S, et al. Pulse pressure and subclinical cardiovascular damage in primary hypertension. Nephrol Dial Transplant 2002; 17(10): 1779-1785.
30. Trika CD, Zakopoulos N, Toumanidis ST, Stamatelopoulos SD. Pulse pressure and left ventricular dysfunction in hypertensive patients. Cardiology 2004; 102(2): 108-114.
31. Safar ME. Pulse pressure, heart rate and drug treatment of hypertension. Curr Hypertens Rep 2004; 6(3): 190-194.
32. Dart AM, Kingwall BA. Pulse pressure- a review of mechanisms and clinical relevance. J Am Coll Cardiol 2001; 37(4): 975-984.
33. Diez J, Gonzalez A, Lopez B, Ravasassa S, Fortuno MA. Effects of antihypertensive agents on left ventricle: clinical implications. Am J Cardiovasc Drugs 2001; 1(4): 263-279.
34. Hernandez RH, Armas-Hernandez MJ, Velaso M, Israeli ZH, Armas-Padilla MO. Calcium antagonists and atherosclerosis protection in hypertension. Am J Ther 2003; 10(6): 408-414.
35. Agabiti-Rossei I, Muiesan ML. Left ventricular hypertrophy: how to influence an important risk factor in hypertension. J Hypertens 1998; 16(1) Suppl: S53-58.
36. Schunkert H. Obesity and target organ damage: the heart. Int J Obes Relat Metab Disord 2002; 26(Suppl 4): S15-20.
37. De Cailar G, Ribstein J, Mimran A. Dietary sodium and target organ damage in essential hypertension. Am J Hypertens 2002; 15(3): 222-229.
38. Kannel WB, Vasan RS. Assessment of cardiovascular risk and choice of antihypertensive therapy. Curr Hypertens Rep 2004; 65(5): 346-351.
39. Sowers JR, Frolich ED. Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med Clin North Am 2004; 88(1): 63-82.
40. Horio T, Miyazato J, Kamide K, Takiuchi S, Kawano Y. Influence of low high-density lipoprotein cholesterol on left ventricular hypertrophy and diastolic dysfunction in essential hypertension. Am J Hypertens 2003; 16(11 Pt 1): 938-944.
41. Shillaci G, Vaudo G, Reboldi G, Verdecchia P, Lupattelli G, Pasqualini L, et al. High-density lipoprotein cholesterol and left ventricular hypertrophy in essential hypertension. J Hypertens 2001; 19(12): 2265-2270.
42. Luppateli G, Marchesi S, Lombardini R, Siepi D, Bogaglia F, Pirro M, et al. Mechanisms of HDL effects on endothelial dysfunction in hyperlipidemia. Metabolism 2003; 52(9): 1191-1195.
43. Shaul PW, Mineo C. HDL action on the vascular wall: is the answer NO? J Clin Invest 2004; 13(4): 509-513.
44. Fried SK, Rao SP. Sugars, hypertriglyceridemia and cardiovascular disease. Am J Clin Nutr 2003; 78(4): 873S-880S.
45. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, Wee DY. Reverse epidemiology: a spurious hypothesis or a hardcore reality? Blood Purif 2005; 23(1): 57-63.
46. Ramos R, Marrugat J, Basagana X, Sala J, Masia R, Elosua R. REGICOR investigators. The role of aging in cardiovascular risk factors clustering in non-diabetic population free of coronary heart disease. Eur J Clin Epidemiol 2004; 109(23 Suppl): III 15-19.
47. Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004; 43(10): 1817-1822.